Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

Xenofon Baraliakos; Mikkel Østergaard; Denis Poddubnyy; Désirée van der Heijde; Atul Deodhar; Pedro M Machado; Victoria Navarro-Compán; Kay-Geert Hermann; Mitsumasa Kishimoto; Eun Young Lee; Lianne S Gensler; Uta Kiltz; Marco Eigenmann; Patricia Pertel; Aimee Readie; Hanno B. Richards; Brian Porter; Juergen Braun

Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

Xenofon Baraliakos
, Mikkel Østergaard
, Denis Poddubnyy
, Désirée van der Heijde
, Atul Deodhar
, Pedro M Machado
, Victoria Navarro-Compán
, Kay-Geert Hermann
, Mitsumasa Kishimoto
, Eun Young Lee
, Lianne S Gensler
, Uta Kiltz
, Marco Eigenmann
, Patricia Pertel
, Aimee Readie
, Hanno B. Richards
, Brian Porter
, Juergen Braun

Department for Rheumatology and Spine Diseases

Abstract

Background/Purpose:
Biologics are clinically efficacious in patients (pts) with axial spondyloarthritis (axSpA) including radiographic axSpA (r-axSpA). Limited data exist on the effect of biologics in slowing radiographic progression in pts with r-axSpA. Two-year data from MEASURE 1 showed low radiographic progression with secukinumab (SEC).1 We report data from SURPASS,2 the first head-to-head study in r-axSpA, that compared the effect of SEC vs adalimumab biosimilar (SDZADL) on spinal radiographic progression.

Original language	English
Publication date	2023
Publication status	Published - 2023
Event	EULAR 2023 - Milano, Italy Duration: 31 May 2023 → 2 Jun 2023

Conference

Conference	EULAR 2023
Country/Territory	Italy
City	Milano
Period	31/05/2023 → 02/06/2023

Cite this

Baraliakos, X., Østergaard, M., Poddubnyy, D., Heijde, D. V. D., Deodhar, A., Machado, P. M., Navarro-Compán, V., Hermann, K.-G., Kishimoto, M., Lee, E. Y., Gensler, L. S., Kiltz, U., Eigenmann, M., Pertel, P., Readie, A., Richards, H. B., Porter, B., & Braun, J. (2023). Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study. Annals of the Rheumatic Diseases 82, Suppl. 1: 38. Abstract from EULAR 2023, Milano, Italy.

Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study. / Baraliakos, Xenofon; Østergaard, Mikkel; Poddubnyy, Denis et al.
2023. Annals of the Rheumatic Diseases 82, Suppl. 1: 38 Abstract from EULAR 2023, Milano, Italy.

Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

Baraliakos, X, Østergaard, M, Poddubnyy, D, Heijde, DVD, Deodhar, A, Machado, PM, Navarro-Compán, V, Hermann, K-G, Kishimoto, M, Lee, EY, Gensler, LS, Kiltz, U, Eigenmann, M, Pertel, P, Readie, A, Richards, HB, Porter, B & Braun, J 2023, 'Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study', EULAR 2023, Milano, Italy, 31/05/2023 - 02/06/2023 pp. Annals of the Rheumatic Diseases 82, Suppl. 1: 38.

@conference{c4e84a632c9f469c9e8969748d39d96d,

title = "Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study",

abstract = "Background/Purpose: Biologics are clinically efficacious in patients (pts) with axial spondyloarthritis (axSpA) including radiographic axSpA (r-axSpA). Limited data exist on the effect of biologics in slowing radiographic progression in pts with r-axSpA. Two-year data from MEASURE 1 showed low radiographic progression with secukinumab (SEC).1 We report data from SURPASS,2 the first head-to-head study in r-axSpA, that compared the effect of SEC vs adalimumab biosimilar (SDZADL) on spinal radiographic progression.",

author = "Xenofon Baraliakos and Mikkel {\O}stergaard and Denis Poddubnyy and Heijde, \{D{\'e}sir{\'e}e van der\} and Atul Deodhar and Machado, \{Pedro M\} and Victoria Navarro-Comp{\'a}n and Kay-Geert Hermann and Mitsumasa Kishimoto and Lee, \{Eun Young\} and Gensler, \{Lianne S\} and Uta Kiltz and Marco Eigenmann and Patricia Pertel and Aimee Readie and Richards, \{Hanno B.\} and Brian Porter and Juergen Braun",

note = "COPECARE; EULAR 2023 ; Conference date: 31-05-2023 Through 02-06-2023",

year = "2023",

language = "English",

pages = "Annals of the Rheumatic Diseases 82, Suppl. 1: 38",

}

TY - ABST

T1 - Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

AU - Baraliakos, Xenofon

AU - Østergaard, Mikkel

AU - Poddubnyy, Denis

AU - Heijde, Désirée van der

AU - Deodhar, Atul

AU - Machado, Pedro M

AU - Navarro-Compán, Victoria

AU - Hermann, Kay-Geert

AU - Kishimoto, Mitsumasa

AU - Lee, Eun Young

AU - Gensler, Lianne S

AU - Kiltz, Uta

AU - Eigenmann, Marco

AU - Pertel, Patricia

AU - Readie, Aimee

AU - Richards, Hanno B.

AU - Porter, Brian

AU - Braun, Juergen

N1 - COPECARE

PY - 2023

Y1 - 2023

N2 - Background/Purpose: Biologics are clinically efficacious in patients (pts) with axial spondyloarthritis (axSpA) including radiographic axSpA (r-axSpA). Limited data exist on the effect of biologics in slowing radiographic progression in pts with r-axSpA. Two-year data from MEASURE 1 showed low radiographic progression with secukinumab (SEC).1 We report data from SURPASS,2 the first head-to-head study in r-axSpA, that compared the effect of SEC vs adalimumab biosimilar (SDZADL) on spinal radiographic progression.

AB - Background/Purpose: Biologics are clinically efficacious in patients (pts) with axial spondyloarthritis (axSpA) including radiographic axSpA (r-axSpA). Limited data exist on the effect of biologics in slowing radiographic progression in pts with r-axSpA. Two-year data from MEASURE 1 showed low radiographic progression with secukinumab (SEC).1 We report data from SURPASS,2 the first head-to-head study in r-axSpA, that compared the effect of SEC vs adalimumab biosimilar (SDZADL) on spinal radiographic progression.

M3 - Conference abstract for conference

SP - Annals of the Rheumatic Diseases 82, Suppl. 1: 38

T2 - EULAR 2023

Y2 - 31 May 2023 through 2 June 2023

ER -

Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study

Abstract

Conference

Fingerprint

Cite this